These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
942 related articles for article (PubMed ID: 16154481)
1. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study. Sittl R; Nuijten M; Nautrup BP Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481 [TBL] [Abstract][Full Text] [Related]
2. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Sittl R; Likar R; Nautrup BP Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486 [TBL] [Abstract][Full Text] [Related]
3. Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany. Sittl R; Nuijten M; Poulsen Nautrup B Clin Ther; 2006 Aug; 28(8):1144-1154. PubMed ID: 16982291 [TBL] [Abstract][Full Text] [Related]
4. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
5. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Sorge J; Sittl R Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693 [TBL] [Abstract][Full Text] [Related]
6. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. Likar R; Kayser H; Sittl R Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176 [TBL] [Abstract][Full Text] [Related]
7. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study. Mercadante S; Porzio G; Ferrera P; Aielli F; Verna L; Tirelli W; Villari P; Casuccio A Clin Ther; 2009 Oct; 31(10):2134-8. PubMed ID: 19922884 [TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159 [TBL] [Abstract][Full Text] [Related]
9. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison. Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542 [TBL] [Abstract][Full Text] [Related]
10. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study. Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study. Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818 [TBL] [Abstract][Full Text] [Related]
12. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients. Griessinger N; Sittl R; Likar R Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522 [TBL] [Abstract][Full Text] [Related]
13. Transdermal buprenorphine in cancer pain and palliative care. Sittl R Palliat Med; 2006; 20 Suppl 1():s25-30. PubMed ID: 16764218 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386 [TBL] [Abstract][Full Text] [Related]
15. Improved cancer pain treatment using combined fentanyl-TTS and tramadol. Marinangeli F; Ciccozzi A; Aloisio L; Colangeli A; Paladini A; Bajocco C; Coaccioli S; Varrassi G Pain Pract; 2007 Dec; 7(4):307-12. PubMed ID: 17986161 [TBL] [Abstract][Full Text] [Related]
16. Buprenorphine TDS: use in daily practice, benefits for patients. Radbruch L Int J Clin Pract Suppl; 2003 Feb; (133):19-22; discussion 23-4. PubMed ID: 12665120 [TBL] [Abstract][Full Text] [Related]
17. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain. Mitra F; Chowdhury S; Shelley M; Williams G Pain Med; 2013 Jan; 14(1):75-83. PubMed ID: 23320402 [TBL] [Abstract][Full Text] [Related]
18. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain. Tawfik MO; Bryuzgin V; Kourteva G; Curr Med Res Opin; 2004 Mar; 20(3):259-67. PubMed ID: 15025835 [TBL] [Abstract][Full Text] [Related]
19. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Simpson DM; Messina J; Xie F; Hale M Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282 [TBL] [Abstract][Full Text] [Related]
20. Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age. Likar R; Vadlau EM; Breschan C; Kager I; Korak-Leiter M; Ziervogel G Clin J Pain; 2008; 24(6):536-43. PubMed ID: 18574363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]